Nighttime insomnia treatment and education for Alzheimer's disease: A randomized, controlled trial

被引:196
|
作者
McCurry, SM
Gibbons, LE
Logsdon, RG
Vitiello, MV
Teri, L
机构
[1] Univ Washington, Dept Psychosocial & Community Hlth, Seattle, WA 98115 USA
[2] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98115 USA
关键词
sleep; nocturnal disturbances; Alzheimer's disease; caregivers; actigraphy;
D O I
10.1111/j.1532-5415.2005.53252.x
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
OBJECTIVES: To evaluate whether a comprehensive sleep education program (Nighttime Insomnia Treatment and Education for Alzheimer's Disease (NITE-AD)) could improve sleep in dementia patients living at home with their family caregivers. DESIGN: A randomized, controlled trial. PARTICIPANTS: Thirty-six community-dwelling patients with Alzheimer's disease (AD) and their family caregivers. INTERVENTION: All participants received written materials describing age- and dementia-related changes in sleep and standard principles of good sleep hygiene. Caregivers in active treatment (n=17) received specific recommendations about setting up and implementing a sleep hygiene program for the dementia patient and training in behavior management skills. Patients in active treatment were also instructed to walk daily and increase daytime light exposure with the use of a light box. Control subjects (n=19) received general dementia education and caregiver support. MEASUREMENTS: Primary sleep outcomes were derived for patients and caregivers from 1 week of sleep-wake activity measured at baseline, posttest (2 months), and 6-month follow-up using an Actillume wrist-movement recorder. Secondary patient outcomes included the Epworth Sleepiness Scale, the Cornell Depression Scale, and the Revised Memory and Behavior Problem Checklist. Caregiver self-reports included the Pittsburgh Sleep Quality Index and the Center for Epidemiological Study of Depression Scale. RESULTS: Patients participating in NITE-AD showed significantly greater (P <.05) posttest reductions in number of nighttime awakenings, total time awake at night, and depression, and increases in weekly exercise days than control subjects. At 6-month follow-up, treatment gains were maintained, and additional significant improvements in duration of night awakenings emerged. When cognitive level was controlled, NITE-AD patients had lower longitudinal ratings of daytime sleepiness than controls. There was a trend for control subjects to spend more time in bed at 6 months than NITE-AD patients. CONCLUSION: This study provides the first evidence that patients with AD who are experiencing sleep problems can benefit from behavioral techniques (specifically, sleep hygiene education, daily walking, and increased light exposure) that are known to improve sleep in nondemented, institutionalized older adults.
引用
收藏
页码:793 / 802
页数:10
相关论文
共 50 条
  • [1] A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease
    Rockwood, K
    Beattie, BL
    Eastwood, MR
    Feldman, H
    Mohr, E
    PrysePhillips, W
    Gauthier, S
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1997, 24 (02) : 140 - 145
  • [2] A randomized controlled trial of estrogen for the treatment of Alzheimer's disease in women
    Henderson, VW
    Paganini-Hill, A
    Miller, BL
    Elble, RJ
    Reyes, PF
    Farlow, MR
    NEUROLOGY, 2000, 54 (07) : A470 - A470
  • [3] RANDOMIZED CONTROLLED CLINICAL POLYSOMNOGRAPHY TRIAL OF SUVOREXANT FOR TREATING INSOMNIA IN PATIENTS WITH ALZHEIMER'S DISEASE
    Herring, W. Joseph
    Ceesay, Paulette
    Snyder, Ellen
    Bliwise, Donald
    Budd, Kerry
    Hutzelmann, Jill
    Stevens, Joanne
    Michelson, David
    SLEEP, 2019, 42
  • [4] A randomized controlled trial of prednisone in Alzheimer's disease
    Aisen, PS
    Davis, KL
    Berg, JD
    Schafer, K
    Campbell, K
    Thomas, RG
    Weiner, MF
    Farlow, MR
    Sano, M
    Grundman, M
    Thal, LJ
    NEUROLOGY, 2000, 54 (03) : 588 - 593
  • [5] A RANDOMIZED CONTROLLED TRIAL OF SUVOREXANT FOR TREATING INSOMNIA IN PATIENTS WITH ALZHEIMER'S DISEASE: EFFECTS ON OBJECTIVE SLEEP MEASURES
    Herring, W. J.
    Ceesay, P.
    Snyder, E.
    Bliwise, D.
    Budd, K.
    Hutzelmann, J.
    Stevens, J.
    Michelson, D.
    SLEEP MEDICINE, 2019, 64 : S153 - S153
  • [6] Combination Treatment in Alzheimer's Disease: Results of a Randomized, Controlled Trial with Cerebrolysin and Donepezil
    Alvarez, X. A.
    Cacabelos, R.
    Sampedro, C.
    Couceiro, V.
    Aleixandre, M.
    Vargas, M.
    Linares, C.
    Granizo, E.
    Garcia-Fantini, M.
    Baurecht, W.
    Doppler, E.
    Moessler, H.
    CURRENT ALZHEIMER RESEARCH, 2011, 8 (05) : 583 - 591
  • [7] A randomized controlled trial of prednisone in Alzheimer's disease - Reply
    Aisen, PS
    Grundman, M
    Thomas, RG
    Thal, LJ
    NEUROLOGY, 2000, 55 (07) : 1067 - 1067
  • [8] A Randomized Controlled Trial of a Yoga Treatment for Chronic Insomnia
    Khalsa, Sat Bir Singh
    APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK, 2010, 35 (02) : 179 - 179
  • [9] The efficacy of statins in the treatment of Alzheimer's disease: a meta-analysis of randomized controlled trial
    Xuan, Kun
    Zhao, Tianming
    Qu, Guangbo
    Liu, Haixia
    Chen, Xin
    Sun, Yehuan
    NEUROLOGICAL SCIENCES, 2020, 41 (06) : 1391 - 1404
  • [10] Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial
    Rockwood, K
    Fay, S
    Song, XW
    MacKnight, C
    Gorman, M
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (08) : 1099 - 1105